Compare SKLZ & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKLZ | COYA |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.6M | 97.8M |
| IPO Year | 2020 | 2022 |
| Metric | SKLZ | COYA |
|---|---|---|
| Price | $8.84 | $5.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $14.00 | ★ $15.80 |
| AVG Volume (30 Days) | ★ 243.6K | 173.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,496,000.00 | $7,945,753.00 |
| Revenue This Year | $28.27 | N/A |
| Revenue Next Year | $11.01 | $763.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 12.52 | ★ 123.57 |
| 52 Week Low | $2.23 | $3.71 |
| 52 Week High | $20.00 | $7.75 |
| Indicator | SKLZ | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 58.37 |
| Support Level | $8.20 | $4.45 |
| Resistance Level | $10.25 | $5.18 |
| Average True Range (ATR) | 0.78 | 0.36 |
| MACD | -0.20 | 0.06 |
| Stochastic Oscillator | 37.33 | 72.50 |
Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. The company's reportable business segments are: the Skillz segment and the RZR segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is a performance marketing platform that enables advertisers to acquire, retain, and monetize users across mobile, connected television (CTV), and other digital channels. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The majority of its revenue is generated from the Skillz segment. Geographically, the company derives its key revenue from the United States.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.